Clinical Trials Browser

Phase 2 × Deferoxamine × Clear all

NCT05300958 2025-07-22

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Phase 2 Terminated

Triple Negative Breast Neoplasms